New Hope for Aggressive Melanoma

A novel approach using an established immunotherapy drug, pembrolizumab, has shown remarkable success in treating desmoplastic melanoma, a rare and aggressive skin cancer. A recent clinical trial found that pembrolizumab can significantly shrink, and even eliminate, tumors associated with this challenging condition.

During the study, 71% of patients undergoing treatment with pembrolizumab experienced no detectable cancer by the time their tumors were surgically removed. This pre-surgical immunotherapy regimen is reported to be both powerful and safe, reducing the necessity for invasive surgical procedures.

Researchers noted that desmoplastic melanoma, which accounts for about 4% of all melanomas, can be difficult to remove surgically due to its tendency to grow deep into tissues. The success of pembrolizumab in this trial, with 95% of patients alive and 74% remaining cancer-free at three years, marks a significant shift in treatment strategies.